Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 18/20 | 0.52 |
| ▸ | CASP3 | P42574 | 3/20 | 0.52 |
| ▸ | CASP7 | P55210 | 2/20 | 0.52 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.52 |
| ▸ | CASP9 | P55211 | 1/20 | 0.46 |
| ▸ | CASP6 | P55212 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL487503 | 1.00 | CASP1 (0.52) | CASP1CASP3CASP7CASP8CASP9 | |
| SCHEMBL487502 | 1.00 | CASP1 (0.52) | CASP1CASP3CASP7CASP8CASP9 | |
| SCHEMBL14664258 | 1.00 | CASP1 (0.52) | CASP1CASP3CASP7CASP8CASP9 | |
| SCHEMBL8267295 | 0.89 | CASP1 (0.56) | CASP1CASP3CASP7CASP8 | |
| SCHEMBL487072 | 0.89 | CASP1 (0.56) | CASP1CASP3CASP7CASP8 | |
| SCHEMBL14664250 | 0.89 | CASP1 (0.58) | CASP1CASP3CASP7CASP8 | |
| SCHEMBL487439 | 0.89 | CASP1 (0.58) | CASP1CASP3CASP7CASP8 | |
| SCHEMBL14664263 | 0.89 | CASP1 (0.52) | CASP1CASP3CASP7CASP8 | |
| SCHEMBL487437 | 0.89 | CASP1 (0.58) | CASP1CASP3CASP7CASP8 | |
| SCHEMBL14664259 | 0.89 | CASP1 (0.56) | CASP1CASP3CASP7CASP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362043-B2 | Use in controlling apoptosis, as antiinflammatory agents, in treating autoimmune disease, as antiischemic agents, in treating cardiovascular disorders; for example, 3(R,S)-[2(S)-(3-Benzoylamino-2-oxo-2H-pyridin-1-yl)-3-phenyl-propionylamino]-5-fluoro-4-oxo-pentanoic acid | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-29 | — | — | US | disclosed |
| EP-1833794-B1 | 3-[2-(3-ACYLAMINO-2-OXO-2H-PYRIDIN-1-YL)-ACETYLAMINO]-4-OXO-PENTANOIC ACID DERIVATIVES AND THEIR USE AS CASPASE INHIBITORS | VERTEX PHARMA (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20060160862-A1 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160862-A1 | Caspase inhibitors and uses thereof | CASP1, CASP5, CASP3 | CASP1 1/4885CASP3 3/4885CASP7 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.